Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients

Biological Psychiatry

Volumn 68, Issue 7, 2010, Pages 678-680

  Feifel, David ^a   MacDonald, Kai ^a   Nguyen, Angel ^a   Cobb, Patrice ^a   Warlan, Heather ^a   Galangue, Barbara ^a   Minassian, Arpi ^a   Becker, Olga ^a   Cooper, Jason ^a   Perry, William ^a   Lefebvre, Mischelle ^b   Gonzales, James ^b   Hadley, Allison ^a  

^a UCSD MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Oxytocin; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OXYTOCIN; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; LETHARGY; MALE; MENTAL PATIENT; NAUSEA; NEGATIVE SYNDROME; NOSE IRRITATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SLEEP DISORDER; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYTOCIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77956932186     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.04.039     Document Type: Article

References (19)

1. F.W. van Leeuwen, J. van Heerikhuize, G. van der Meulen, and P. Wolters Light microscopic autoradiographic localization of [3H]oxytocin binding sites in the rat brain, pituitary and mammary gland Brain Res 359 1985 320 325
2. D. Feifel, and T. Reza Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating Psychopharmacology (Berl) 141 1999 93 98
3. P.R. Lee, D.L. Brady, R.A. Shapiro, D.M. Dorsa, and J.I. Koenig Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin Neuropsychopharmacology 30 2005 1883 1894
4. H.K. Caldwell, S.L. Stephens, and W.S. Young Oxytocin as a natural antipsychotic: A study using oxytocin knockout mice Mol Psychiatry 14 2009 190 196
5. P. Linkowski, V. Geenen, M. Kerkhofs, J. Mendlewicz, and J.J. Legros Cerebrospinal fluid neurophysins in affective illness and in schizophrenia Eur Arch Psychiatry Neurol Sci 234 1984 162 165
6. H. Beckmann, R.E. Lang, and W.F. Gattaz Vasopressinoxytocin in cerebrospinal fluid of schizophrenic patients and normal controls Psychoneuroendocrinology 10 1985 187 191
7. J.K. Mai, K. Berger, and M.V. Sofroniew Morphometric evaluation of neurophysin-immunoreactivity in the human brain: Pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia J Hirnforsch 34 1993 133 154
8. J.J. Legros, C. Gazzotti, T. Carvelli, P. Franchimont, M. Timsit-Berthier, R. von Frenckell, and M. Ansseau Apomorphine stimulation of vasopressin- and oxytocin-neurophysins Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics Psychoneuroendocrinology 17 1982 611 617
9. M. Goldman, M. Marlow-O'Connor, I. Torres, and C.S. Carter Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits Schizophr Res 98 2008 247 255
10. S. Keri, I. Kiss, and O. Kelemen Sharing secrets: Oxytocin and trust in schizophrenia Soc Neurosci 4 2008 287 293
11. D. Glovinsky, K.T. Kalogeras, D.G. Kirch, R. Suddath, and R.J. Wyatt Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication Schizophr Res 11 1994 273 276
12. M. Kosfeld, M. Heinrichs, P.J. Zak, U. Fischbacher, and E. Fehr Oxytocin increases trust in humans Nature 435 2005 673
13. A. Theodoridou, A.C. Rowe, I.S. Penton-Voak, and P.J. Rogers Oxytocin and social perception: Oxytocin increases perceived facial trustworthiness and attractiveness Horm Behav 56 2009 128 132
14. S.R. Kay, A. Fiszbein, and L.A. Opler The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
15. W. Guy, R.R. Bonato, Manual for the ECDEU Assessment Battery, Revised 2nd ed. 1970 National Institute of Mental Health Chevy Chase, MD 12.1 12.6
16. B. Ravina, M. Putt, A. Siderowf, J.T. Farrar, M. Gillespie, and A. Crawley Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study J Neurol Neurosurg Psychiatry 76 2005 934 939
17. J. Cohen Statistical Power Analysis for the Behavioral Sciences 2nd ed. 1988 Eribaum Hillsdale, NJ
18. W. Bujanow Letter: Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J 19 1974 323
19. V.D. Bakharev, S.M. Tikhomirov, and T.K. Lozhkina Psychotropic properties of oxytocin Neurosci Behav Physiol 16 1986 160 415